Public-Private Partnerships Can Serve as Important Levers of Innovation
Collaboration was a central theme of the recent BIO International Convention, which featured panel discussions on AMP-lifying Innovation: NIH, Patient Organizations & Leading Biopharma Firms Mobilize to Tackle Tough Diseases and Playing Nice in the Sandbox: Pre-Competitive Research Consortiums Offer Quicker, Less Expensive Path to Better Medicines.
Accelerating Medicines Partnership Aims to Speed Validation of Disease Targets
The Accelerating Medicines Partnership (AMP), an initiative of the National Institutes of Health (NIH), several non-profit disease foundations, 10 biopharmaceutical companies and PhRMA, has the lofty goal of transforming the current model for developing new diagnostics and treatments for patients by joining forces to identify and validate promising biological targets of disease. AMP was launched earlier this year with pilot programs in Alzheimer’s disease, type 2 diabetes and autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus).
In the super session on AMP, Dr. Jan Lundberg of Lilly Research Foundation explained why biopharmaceutical companies invest their time and resources in public private partnerships: to accelerate breakthroughs and increase the efficiency of bringing new medicines to patients. Read More